Becker R, Dembek C, White L, Garrison L. The cost offsets and cost-effectiveness associated with PEGylated drugs: a review of the literature, Expert Rev. Pharmacoecon. Outcomes Res. 12(6), 775–793 (2012).
Becker R. Potential economic benefits of pegylation in the treatment of multiple sclerosis: A systematic review of the pharmacoeconomic literature. ISPOR International Conference, June 2012 (Abs.)
Becker R. Potential humanistic benefits of pegylation in the treatment of multiple sclerosis: A systematic review of the literature. ISPOR International Conference, June 2012 (Abs).
Becker RV. Potential Benefits of Pegylation in the Treatment of Multiple Sclerosis: A Systematic Review of the Pharmacoeconomic Literature. 15th European Federation of Neuorological Societies Congress, Budapest, September 2011 (Abs.).
Becker RV, Dembek C. Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis. J Manag Care Pharm. 2011;17(5):377-81.
Becker RV, Dembek C. Data Selection Considerations in Cost-Effectiveness Analyses in Multiple Sclerosis 63rd Annual Meeting of the American Academy of Neurology (AAN), Honolulu April 2011 (abs.)
Becker RV, Dembek C. Impact of Cohort Selection on Cost-effectiveness Results in Multiple Sclerosis, Value Health, 2010, 13:7: A392 (Abs.)
Cowles V, Becker R, Miller J, Sweeny M. A novel gastroretentive formulation of gabapentin for the treatment of postherpetic neuralgia. AJMC, Nov. 2012, Suppl.
Becker R, Miller K, McIntosh J, Miller J, Sweeney M. Budget impact and cost-effectiveness of once-daily gabapentin for the treatment of postherpetic neuralgia. ISPOR International Conference, June 2012 (Abs.).
Becker RV, Burke T, McCoy M, Trotter J. Cost of blood pressure destabilization and edema associated with rofecoxib and celecoxib among patients with osteoarthritis and hypertenstion, Clin Ther, 2003; 25(2):647-662.
Becker RV, Wong A, Forte L, Miller B. An economic evaluation of the cost of cardiorenal and gastrointestinal events in elderly coxib-treated patients, Canadian Association of Population Therapeutics Annual Meeting, Quebec City, Canada, March 2003 (Abs.).
Becker RV, Burke T, Williamson T, Trotter JP. An economic evaluation of the cost of edema and systolic blood pressure destabilization in cox-2-treated patients with osteoarthritis and hypertension. Value Health. 2001 Nov-Dec;4(6):485 (Abs.).
Benner J, Becker R, Fanning K, et.al. Bother related to bladder control and healthcare-seeking behavior in US adults. J Urol. 2009 Jun;181(6):2591-8. Epub 2009 Apr 16.
Brubaker L, Nichol M, Fanning T, Becker R, Jumadilova Z, Benner J Patient-Reported Reasons for Discontinuing Overactive Bladder (OAB) Medications. Annual International Continence Society Meeting, November 2006 (Abs.).
Albo M, Rovner E, Mullins C, Becker R, Jumadilova Z, Benner J. Overactive bladder symptom bother is more prevalent in men than women at older ages. Poster presented at American Urology Association Western Section Meeting, October 2006 (Abs., Third place award.)
Rovner E, Albo M, Mullins C, Becker R, Jumadilova Z, Benner J. Overactive bladder symptom bother is more prevalent in men than women at older ages. American Urology Association Southeastern Section Meeting, March 2007 (Abs.).
Noe LL, Becker RV, Williamson T, Chen DM. A pharmacoeconomic model comparing two long-acting treatments of overactive bladder. J Manag Care Pharm. 2002;8(5):343-352.
Noe LL, Becker RV, Chen DM, Williamson T. A straightforward cost-effectiveness analysis of long-acting treatments for overactive bladder: can it be this simple? Value Health. 2002;5(6):582-583 (Abs.).
Becker RV, Noe LL, Chen DM, Williamson T. Evaluating the cost of long-acting treatments for overactive bladder. Value Health. 2002;5(6):583 (Abs.).
Becker RV, Noe LL, Trotter JP and Williamson TE. A cost-effective comparison of extended-release tolterodine (Detrol LA) versus controlled-release oxybutynin (Ditropan XL). Proceedings of the South Central Section of the American Urological Association (AUA) Annual Conference; 2001 Sept; Austin (Abs.).
El Hashem G, Becker R, Maskineh C. Evaluating adverse costs in cancer patients in Lebanon from two payer perspectives. 20th Annual ISPOR European Congress, Glasgow, Scotland, Nov. 2017. (Abs.)
Zeuger P, Becker R. The affordability of oncology and HIV/AIDS technologies in Brazil compared to the United States and other OECD countries. 4th Latin American ISPOR conference, Sept. 2013. Buenos Aires, Argentina (Abs.).
Becker R, Salamone S, Choma A, Kenny P, Hollenbeak C. Cost-effectiveness of pharmacokinetic dosing of 5-fluorouracil in metastatic colorectal cancer in the U.K. 18th Annual ISPOR International Conference, June 2013, New Orleans, Louisiana (Abs.).
Becker R, Noe L, Gore M, Chen D. Incorporating clinical level-of-evidence criteria into a breast cancer treatment model for Japan. Value Health. 2001 Nov-Dec;4(6):421 (Abs.).
Becker R, Noe L, Gore M, Chen D. Using level of evidence criteria in the evaluation of pharmacoeconomic results. Value Health. 2001 Nov-Dec;4(6):432 (Abs.).
Becker RV, Noe L, Gore M, Martino S, Eiermann W, Namer M, Howell A, Bianco A, Watanabe T. Disease modeling: Developing the infrastructure for a comprehensive, multinational, clinical and economic breast cancer treatment model. Value Health. 2001;4(2):93 (Abs.).
Noe L, Becker R, Gradishar W, et. al. The cost-effectiveness of tamoxifen in the prevention of breast cancer, The American Journal of Managed Care, Vol. 5. No. 6., June 1999, p. s389 – s406.
Noe L, Becker R, Gradishar W, et. al. The cost-effectiveness of tamoxifen in reducing the Incidence of breast cancer, ASCO Annual Meeting, May, 1999 (Abs.).
Hanauer S, Cohen R, Becker R, et. al. Advances in the management of Crohn’s disease: Economic and clinical potential of Infliximab, Clin Ther, Vol. 20, No. 5, Sept.-Oct. 1998, p. 1009 – 1028.
Zeuger P, Becker R. The affordability of oncology and HIV/AIDS technologies in Brazil compared to the United States and other OECD countries. 4th Latin American ISPOR conference, Sept. 2013. Buenos Aires, Argentina (Abs.).
Becker R, Teich V, Pepe C. National cost savings from Brazil’s HIV/AIDS antiretroviral universal access program: Analysis versus Canada and Australia. ISPOR European Conference, Nov. 2011 (Abs.).
Teich V, Becker RV, Pepe C. National cost savings from Brazil’s HIV/AIDS antiretroviral universal access program. 8th Annual Health Technology Assessment International (HTAi) Conference, Rio de Janeiro, Brazil, June 27, 2011 (Abs.).
Ho J, Becker R. The economic impact of lower HIV prevalence estimates. ISPOR European Conference, Nov. 2008 (Abs.).
Flavin F, Becker R. Cost savings from reduced HIV incidence estimates. ISPOR International Conference, May 2008 (Abs.).
Becker R, Affordability of universal access targets in 20 Latin American countries. ISPOR Latin American Conference, Sept. 2007 (Abs.).
Becker R, Munkata J. Estimating the GDP saved due to AIDS treatment. Value Health 2007: 10(3): A169 (Abs.).
Becker R, Benner J. Incorporating compliance rates into the cost of treating HIV/AIDS in two African countries. Value Health 2005: 8(6): A61 (Abs.).
Becker RV, Stegman J. Impact of recent ritonovir re-pricing on cost-effectiveness analysis. Value Health Nov-Dec 2004: 7(6):638 (Abs.).
Becker RV, Gams E, Shakur I. Estimated cost savings of discontinuing secondary prophylaxis for opportunistic infections after immunological reconstitution with HAART. Value Health. 2003;6(3):261 (Abs.).
Becker RV, Zaccagnini P, Rattana S. The cost of antiretroviral therapy in three Central American Countries. Value Health. 2002;5(3):123-4 (Abs.).
Becker RV, Zaccagnini P, Rattana S. Impact of adopting Brazil’s antiretroviral drug pricing in three Central American countries. Proceedings of the XIV International Conference on AIDS; 2002 Jul; Barcelona, Spain (Abs.).
Becker RV, Shakur I. Cost-effectiveness of salvage therapy with delavirdine in NNRTI-naïve patients failing indinavir. Proceedings of the XIV International Conference on AIDS; 2002 Jul; Barcelona, Spain (Abs.).
Becker RV, Shakur U. The impact of drug compliance on the cost of treating HIV/AIDS in Africa. Value Health. 2001 Nov-Dec;4(6):439-40 (Abs.).
Savage GE, Gable C, Motte K, Dixon C, Becker RV. A pharmacoeconomic analysis of Kaposi’s sarcoma Patients based on a clinical trial of ABV vs. DaunoXome. Proceedings of the XI International Conference on AIDS; 1996 Jul; Vancouver, Canada (Abs.).
Deitelzweig S, Becker R, Lin J, Benner J,. Comparison of the two-year clinical outcomes of VTE prophylaxis options in medical patients at risk of VTE. Thrombosis and Haemostasis Thromb Haemost. 2008 Nov;100(5):810-20.
Deitelzweig S, Lin J, Benner J, Becker R. Comparison of the two-year clinical outcomes of VTE prophylaxis options in medical patients at risk of VTE. Annual American Society of Hypertension Meeting, May 2008 (Abs.).
Deitelzweig S, Lin J, Benner J, Becker R. Two-year costs of enoxaparin prophylaxis, unfractionated heparin prophylaxis, or no prophylaxis in medical patients at risk of venous thromboembolism. Annual Society of Hospital Medicine Meeting, April 2008 (Abs.).
Deitelzweig S, Lin J, Becker R, Benner J. Identifying VTE prophylaxis-related costs and outcomes. Institure for Healthcare Improvement Annual National Forum on Quality Improvement in Health Care, December 2007 (Abs.).
Becker R, Klingman D Potential medical offsets of treatment with isosorbide dinitrate plus hydarlazine in African-Americans with heart failure. Value Health. 2005;8(6):265 (Abs.).
Becker R, Battleman, D, Zhang H. Comparing the costs of extended-release OROS methylphenidate and immediate-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). 19th Annual Meeting and Showcase, of the Academy of Managed Care Pharmacy, April 2007 (Abs.).
Becker R, Dembek C, White L, Garrsion L. The cost offsets and cost-effectiveness associated with PEGylated drugs: a review of the literature, Expert Rev. Pharmacoecon. Outcomes Res. 12(6), 775–793 (2012).
Becker R. Potential economic benefits of pegylation in the treatment of multiple sclerosis: A systematic review of the pharmacoeconomic literature. ISPOR International Conference, June 2012 (Abs.)
Becker R. Potential humanistic benefits of pegylation in the treatment of multiple sclerosis: A systematic review of the literature. ISPOR International Conference, June 2012 (Abs).
Becker R. Economic benefits of pegylation: A systematic review of the literature, 15th Congress of the European Federation of Neurological Societies (EFNS), Budapest, Hungary, September 11, 2011 (Abs.).
Becker R. Introduction to Budget Impact Analysis (Part I) Long-Distance Learning Module for the ISPOR website (Access at: https://www.ispor.org/distancelearning/Introduction-to-Budget-Impact-Analysis.asp), February 2017.
Becker R. Introduction to Budget Impact Analysis (Part II) Long-Distance Learning Module for the ISPOR website (Access at: https://www.ispor.org/distancelearning/Introduction-to-Budget-Impact-Analysis.asp), February 2017.
Becker R. Introduction to Budget Impact Modeling (Podium Presentation), Second Annual Meeting of Lebanese Chapter of ISPOR, Beirut, Lebanon, February, 2017.
Becker R. Budget Impact Modeling Workshop (Podium Presentation), Second Annual Meeting of Lebanese Chapter of ISPOR, Beirut, Lebanon, February, 2017.
Becker R. Building a Budget Impact Model (Podium Presentation), First Educational Workshop of Lebanese Chapter of ISPOR, Beirut, Lebanon, November, 2016.
Schultz N, Becker R. Variances in the rate of face, internal, and third-party model validity by type of publication, type of model and geographic region. 18th Annual ISPOR International Conference, June 2013, New Orleans Louisiana (Abs.).
Becker R. Third Party Model Validity: A review and survey of face and internal validity of health economic models. ISPOR European Conference, November 2012 (Abs.)
Becker R, Reinhart S. Comparison of two methodologies using gross domestic product to measure affordability of HIV treatment. Proceedings of the 25th Annual Meeting of the Society for Medical Decision Making; 2003 Oct; Chicago, Illinois (Abs.).
Becker R, Noe L, Gore M, Martino S. A new approach to disease modeling with numerous comparators and multiple decision trees. Value Health 2001;4(2):189-190 (Abs.).
Vega C, Becker R, Mucha L, Lorenz B, Eaddy M, Ogbonnaya, A. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder. Curr Med Res Opin. 2017 Oct;33(10):1879-1889.
Vega C, Becker R, Mucha L, Lorenz B, Eaddy M, Ogbonnaya, A. Measurement of adherence to antidepressants and outcomes among patients with both major depressive disorder and type 2 diabetes. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 30 – June 2, 2016; Scottsdale, AZ (Abs.)
Hanlon J, Lenderking W, Hsieh R, Samp J, Becker R, Revicki D. Characteristics of individuals with depression initiating antidepressant therapy in the United States: Baseline results from a prospective longitudinal study. 26th Annual US Psychiatric and Mental Health Congress, September 30–October 2, 2013 Las Vegas, NV (Abs.).
